TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04966819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survivorship Care Initiative
Description: The survivorship initiative will consist of:~(A) Regular meetings with the rectal cancer oncology pivot nurse (IPO). These meetings present an opportunity for patients to discuss any treatment-related distress or late and long-term side-effect.~(B) Identification of a primary care physician. If the patient is not known to a Primary care physician (PCP), the IPO will add the patient to an accelerated waitlist.~(C) Development of an individualized survivorship plan. During meetings with the oncology pivot nurse, a survivorship care plan will be populated, included information on patient risk factors, treatments completed, pathology findings, and future surveillance planned. This document will be reviewed by the treating colorectal surgeon, and will be subsequently shared with the oncology team, the PCP and the patient (if the patient desires).~(D) Educational resources for patients. Patients will be offered educational materials to help address their specific needs.
Study: NCT05158842

Intervention type: DEVICE
Group type: OTHER
Intervention: Adult bubble CPAP oxygen therapy device
Description: In Bubble CPAP, pressurized oxygen from an oxygen cylinder is delivered to the patient. Adjusting the height of the water column above the exit of the tube can regulate the pressure in the system and the amount of CPAP delivered to the patient. Oxygen is delivered by a successfully tested, silicon-based, ergonomically designed adaptive version of nasal canula (nasal seal) inserted into the nostril of a patient.~The components are:~1. Adaptive version of nasal canula (nasal seal)~2. A nasal canula with connecting circuit system~3. Water-filled bottle with marking water pressure from10 to15 L/min.~Oxygen cylinder, central distribution through pipelines or by oxygen concentrator will be used as an oxygen source.
Study: NCT06222242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mychoiceTM
Description: mychoiceTM is an online, educational tool designed to help prepare patients for a conversation with their provider about clinical trials as a treatment option. It consists of text, animations, and videos of real cancer patients sharing their experience with clinical trials. It is not meant to be a recruitment tool, but rather a preparatory tool to promote shared decision making between patients and providers.
Study: NCT06319183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: We will recruit at least 15 male and 15 female volunteers, dividing study participants into two groups based on sex. Before administration, the temperature of the brown adipose tissue area in the scapular region of participants will be recorded using an infrared thermometer. Subsequently, participants will inhale the asthma medication salbutamol according to the safe dosage requirements (100ug). Eight hours later, the temperature changes in the brown adipose tissue area in the scapular region will be detected using an infrared thermometer. During the 8-hour waiting period, the participants' heart rate and blood pressure will be monitored; finally, we will draw 1 milliliter of venous blood from the arm of the participants for blood component analysis. The single trial process will last up to 8 hours, with no follow-up required.
Study: NCT05411380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucidinostat
Description: 20mg each time, orally 30 minutes after dinner, 3 weeks for a cycle, administered on day 1, day 4, day 8, day 11, day 15,and day 18 of each cycle (twice a week, at least 3 days between each administration)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 500mg orally three times a day (continuously)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy
Description: Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily or fulvestrant 500 mg each time, intramuscularly, injected on the 1st day and 15th day of the 1st cycle, and on the 1st day for subsequent cycle( 4 weeks for one cycle)
Study: NCT06553963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The control group maintained their regular diet and training without additional nutritional support.
Study: NCT04814498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geneva Cocktail
Description: Fixed sequence use of drug cocktail

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLD-0409
Description: Fixed sequence use of active product
Study: NCT04535245

Intervention type: DIAGNOSTIC_TEST
Intervention: LCI testing
Description: all subjects will have LCI testing then contacted via a phone interview or EMR review yearly times 5 to determine if they have subsequently developed ILD
Study: NCT04865042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300mg
Description: The patient will receive in addition to the usual analgesic treatment, the treatment under study: Gabapentin.~During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be performed.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The patient will receive in addition to the usual analgesic treatment, the Placebo During the first 3 days of his hospitalization, an evaluation of the pain and the tolerance to the treatment will be made.~The patient will have to take the treatment as follows:~* Day 1 (1st day of hospitalization): 1 capsule/day~* Day 2: 2 capsules/day~* Day 3: 3 capsules/day 72 hours after the first treatment, a blood test will be performed.
Study: NCT06098053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: Muscle energy technique is used at a rate of three sessions per week for four and half weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscel energy technique along with interferential therapy
Description: Muscle energy technique along with interferential therapy is used at a rate of three sessions per week for four and half weeks
Study: NCT05614518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride F-18 Injection
Description: Each subject was given 5-10 mCi intravenously. Images were collected 90-120 min after injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium[99mTc] Methylenediphosphonate Injection
Description: Each subject was given 10-25 mCi intravenously. Images were collected 3-6 hours after injection.
Study: NCT05849623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Mucosal Resection (EMR)
Description: EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cold Endoscopic Mucosal Resection (C-EMR)
Description: C-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Underwater Endoscopic Mucosal Resection (U-EMR)
Description: U-EMR will be used to resect an eligible medium-sized polyp found in patients from this arm.
Study: NCT04978090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D printed EAF management device
Description: Participants will receive a customized 3D printed device based on the EAF's output, size, shape, location, depth, and the participant's wound bed.
Study: NCT06126588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patient will be treat during 7 months of Everolimus
Study: NCT06067607

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eye gaze technology
Description: eye gaze technology and software activities
Study: NCT06520891

Intervention type: DRUG
Intervention: Statin and SGLT2i
Description: Statin as atrovastatin SGLT2i as dapagliflozin

Intervention type: DRUG
Intervention: Statin and SGLT2i
Description: Statin as atrovastatin SGLT2i as dapagliflozin

Intervention type: DRUG
Intervention: Statin and SGLT2i
Description: Statin as atrovastatin SGLT2i as dapagliflozin
Study: NCT06366412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine effect in preventing postoperative cognitive dysfunction on elderly patients undergoing major surgery guided with serum Tau-217 protein.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline will be administrated in placebo group
Study: NCT05271968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global management of scabies
Description: For the interventional arm, the first course of the oral treatment has also to be swallowed at the BOPC service, but the patient will have to come back the following day to take a shower at the BOPC service and will receive new clothes.~The second course will be given, but the patient will have to come back the following day of the second course to take a shower at the BOPC service and to receive again new clothes
Study: NCT06553963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Biochemical Monitoring and Nutritional Support
Study: NCT05508204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: A solution for SC injection administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: A solution for SC injection administered as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BION-1301
Description: A solution for SC injection administered as a single dose
Study: NCT02172001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natrium Chloride 0,9%
Description: 100 ml or 5 ml
Study: NCT06311305

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early Laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy early after ERCP with assessing the risks and complications
Study: NCT04902183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CovenD24
Description: The drug will be administrated once daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CovenD24
Description: The drug will be administrated once daily for 5 days
Study: NCT06546722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Thoracic Plane Block
Description: The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Thoracic Plane Block
Description: The Transversus Thoracic Plane Block is a recent regional anesthesia technique. It provides analgesia for the anterior cutaneous branches of the intercostal nerves T2-6 to the medial anterior chest wall via a single injection of local anesthesia between the internal intercostal muscle and the transversus thoracic muscle located between the third and fourth (or fourth and fifth) intercostal space. It is noteworthy that the TTPB can consequently reduce pulmonary morbidity and the need for high-dose opioids.
Study: NCT05132894

Intervention type: OTHER
Intervention: Osteopathic Assessment
Description: As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.

Intervention type: OTHER
Intervention: Osteopathic Assessment
Description: As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.

Intervention type: OTHER
Intervention: Osteopathic Assessment
Description: As osteopathic structural exam will be performed to assessment somatic dysfunctions of the lower extremities.
Study: NCT05353777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Levita Robotic Platform
Description: Levita Robotic Platform
Study: NCT05250427

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT06415097

Intervention type: DEVICE
Intervention: Insulin Smart Pen
Description: Retrospective analysis of electronic health records for individuals with type 1 diabetes receiving multiple daily doses of insulin, combined with glucose monitoring devices and who have used or are currently using insulin smart pens.
Study: NCT05891951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluid therapy under the guide of Carotid ultrasound
Description: Participants will use carotid ultrasound to assess volume status. If volume is insufficient, fluid therapy will be selected until volume is sufficient. If volume is sufficient, no fluid therapy will be given.
Study: NCT05987020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aromatherapy
Description: The experimental group received aromatherapy, an intervention using lavender essential oil compound, while the control group received a placebo, sweet almond oil.
Study: NCT04309695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenflow Spring System
Description: The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
Study: NCT03422861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nabilone
Description: Treatment regimen will involve nabilone capsule administration starting with 1mg BID orally first administered on POD #0. The patient will be continued on this medication for 72 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Treatment regimen will involve placebo capsule administration, identical in colour, shape, size, taste and smell to the nabilone capsules, starting orally first administered on POD #0. The patient will be continued on this medication for 72 hours
Study: NCT04923347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Description: FF/UMEC/VI will be administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: Participants will receive FF/UMEC/VI using ELLIPTA inhaler.
Study: NCT05442268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acetaminophen group
Description: patients will receive intravenous 500 mg acetaminophen(every 6 hours postoperatively

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duloxetine group
Description: Patients will receive duloxetine 30 mg every 12 hours for 3 days before surgery, 30 mg 2 hours preoperatively and 30 mg 12 hours postoperatively and intravenous 500 mg acetaminophen every 6 hours postoperatively
Study: NCT05472064

Intervention type: OTHER
Intervention: Persona: Primary care doctor
Description: The chatbot persona is a Black woman who is a primary care doctor.

Intervention type: OTHER
Intervention: Persona: Primary care doctor
Description: The chatbot persona is a Black woman who is a primary care doctor.
Study: NCT06345391

Intervention type: OTHER
Intervention: Co-creation
Description: Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.

Intervention type: OTHER
Intervention: Co-creation
Description: Participatory approach maximally and directly involving important stakeholders (bottom-up) to co-create a pain science education intervention for children living beyond cancer.

Intervention type: OTHER
Intervention: Concept Mapping
Description: Concept mapping to create a pain science education intervention for children living beyond cancer.
Study: NCT05472064

Intervention type: OTHER
Intervention: Persona: Breast cancer survivor
Description: The chatbot persona is a Black woman who is a breast cancer survivor.

Intervention type: OTHER
Intervention: Persona: Breast cancer survivor
Description: The chatbot persona is a Black woman who is a breast cancer survivor.

Intervention type: OTHER
Intervention: Communication Style: Direct
Description: The chatbot messages are characterized by commands and direct addresses (''you'').

Intervention type: OTHER
Intervention: Communication Style: Direct
Description: The chatbot messages are characterized by commands and direct addresses (''you'').

Intervention type: OTHER
Intervention: Communication Style: Indirect
Description: The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's).

Intervention type: OTHER
Intervention: Communication Style: Indirect
Description: The chatbot messages are characterized by subjunctive modal verb forms (''would like'') and cooperative addresses (''we, let's).
Study: NCT05995509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-osteo-perforations
Description: small perforations drilled in Alveolar bone, adjacent to site of tooth movement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Micro-osteo-perforations
Description: small perforations drilled in Alveolar bone, adjacent to site of tooth movement.
Study: NCT05633498

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Book
Description: Self-help book describing advice to cope with shift work

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene
Description: Basic sleep hygiene advice on a piece of paper
Study: NCT05648487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC,anti-PD-1 antibody Sintilimab (Tyvyt®), Chemotherapy,Surgery
Description: 1. HIPEC: HIPEC is performed after laparoscopic exploration, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgical exploration.~2. Chemotherapy(SOX) and anti-PD-1 antibody Sintilimab (Tyvyt®) treatment followed (4 cycles): SOX regimen: Oxaliplatin: 130 mg/m\^2, IV, d1; S-1, 40-60 mg/m\^2 bid, po, day 1-14, every 3 weeks for a total of 4 cycles; Sintilimab (Tyvyt®) 200mg fixed dose every 3 weeks, for a total of 4 cycles.~3. Surgery: Imaging and secondary surgical exploration, assess the patient's condition and consider whether perform the cytoreductive surgery (resection of primary tumors and metastases). For patients undergoing surgery, HIPEC for three cycles followed, Mitomycin 30mg/m2, d1, Docetaxel 40mg/m2, d3, Oxaliplatin 65mg/m2, d5 within a week after surgery; For inoperable patients, continue to use standard chemotherapy of guidelines recommend.~4. After the surgery, continue to use standard adjuvant chemotherapy.
Study: NCT05654233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulodexide
Description: The recovery of pigmentation, fibrosis, pain and other indicators in the group taking sulodexide after surgery, one month after surgery and three months after surgery was observed
Study: NCT04692701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulvinar deep brain stimulation
Description: Stimulation of the medial pulvinar
Study: NCT06385184

Intervention type: OTHER
Intervention: No Intervention
Description: Observational study with no intervention

Intervention type: OTHER
Intervention: No Intervention
Description: Observational study with no intervention
Study: NCT05084053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-771
Description: Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)
Study: NCT05858255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergaming
Description: Please see Arms description.
Study: NCT06433297

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS
Description: After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INDIRECT AND DIRECT PULP CAPPING AFTER PARTIAL OR COMPLETE CARIES REMOVAL IN DEEPLY CARIOUS MATURE PERMANENT MANDIBULAR MOLARS WITH MODERATE PULPITIS
Description: After partial caries removal the cavity is disinfected, dried, and capped with a 2-3mm layer of MTA followed by a light-cured resin layer. The tooth is then definitively restored with composite.~Following complete caries removal, any bleeding pulp will be controlled with sodium hypochlorite for up to 5 minutes. Exposed pulp will then be directly capped with a 2-3mm layer of MTA, followed by a light-cured resin layer and definitive composite restoration using an etch-and-rinse technique.
Study: NCT04843579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given as 60 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Given as 500 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given as 4 mg oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given as 40 mg oral capsule
Study: NCT06432114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Awareness Program (SAP)
Description: SAP is a new rehabilitation program for people with severe mental health problems. SAP aims to help the target group manage anxiety outburst and live an active life through sensory modulation techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: Treatment as usual is standard psychiatric care for the target group.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Treatment as usual is standard psychiatric care for the target group.
Study: NCT05354713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVP-1805
Description: NVP-1805 (80/10/20.8mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NVP-1805-R1 and NVP-1805-R2
Description: coadministration of NVP-1805-R1(80mg) and NVP-1805-R2(10/20.8mg)